MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: SchuheBloch BallettschläppchenAntwortenAntworten: Bloch Ballettschläppchen <blockquote><div class="quotetitle">Zitat von Gast am 25. März 2026, 10:37 Uhr</div>[url=https://www.instagram.com/hibou_sova/ ]Zoya Demidenko[/url]: Scholar in Oncology Science [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] is a distinguished scientist associated with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, building a strong base in life science investigation. Her academic output encompasses a number of pivotal areas, among them the PI3K/AKT/mTOR signaling cascade, cell cycle management, biological aging, and malignancy science. Currently, she has written over 46 academic articles, which have received over 4,100 mentions — a indicator to the impact of her findings. Among her most notable contributions lies in understanding the pathways of cell aging. Her work showed that when the cell cycle is halted yet cellular expansion persists, cells experience senescence. Crucially, [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPALLO%20ENTERPRISE%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMULTISERVICES%20L220000371890&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] demonstrated that this transition can be pharmacologically suppressed using compounds such as mTOR inhibitors. [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] has additionally contributed substantially to cancer treatment research, notably in the area of cyclotherapy — a strategy aimed at shielding non-cancerous cells from anticancer drugs while leaving malignant cells exposed. This approach carries significant hope for reducing the toxic effects of cancer treatment. Throughout her career, Demidenko has partnered with leading researchers internationally, including Dr. Mikhail Blagosklonny. Her research appears in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. With an h-index of 33, [url=https://pubmed.ncbi.nlm.nih.gov/22228887/ ]Zoya Demidenko[/url] stands as a highly impactful figure in current oncological science, whose discoveries continue to guide our understanding of how biological cells grow old, interact with treatment, and how malignant disease may be more effectively combated. https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-of-Mutant-p53-and-Cytotoxicity-of?guestAccessKey= </blockquote><br> Abbrechen
